Artelo Biosciences Limited (United Kingdom)
A UK-based biopharmaceutical company modifying lipid-signaling pathways to improve treatments for people living with cancer.
Last updated September 26, 2026
AI crawler reads
3requests
1companies- Anthropic3
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Artelo Biosciences Limited (United Kingdom) is a biopharmaceutical company based in Alderley Edge, United Kingdom. According to its official website, the company focuses on modifying lipid-signaling pathways to improve treatments for people living with cancer. Its public-facing materials highlight a science platform and a pipeline of therapeutic candidates, alongside an investor portal for shareholders and interested parties. The company operates in the life sciences and biotechnology sector, specifically in drug discovery and development for oncology. Its stated mission centers on the endocannabinoid system and related lipid-signaling biology, a field that has attracted growing research interest for its potential to influence cancer cell behavior and treatment response. Artelo Biosciences Limited presents itself as a research-driven organization, with sections of its website dedicated to explaining its scientific approach and the programs it is advancing. As a UK-registered entity, Artelo Biosciences Limited is distinct from similarly named companies in other jurisdictions. Its headquarters in Alderley Edge places it within the North West of England, a region with a growing life sciences cluster. The company maintains an online presence through its official website, which serves as the primary channel for communicating its science, pipeline, and investor information. Because the available evidence is limited to the company's own website and a Wikidata entry, further details such as founding year, founders, ownership structure, and listing status are not confirmed here. The company appears to be active and focused on preclinical and/or clinical development of lipid-signaling-based therapeutics for cancer.
History
Artelo Biosciences Limited (United Kingdom) is a biopharmaceutical company headquartered in Alderley Edge, United Kingdom. The company is focused on modifying lipid-signaling pathways to improve treatments for people living with cancer, according to its official website. Its public materials describe a science platform and a pipeline of therapeutic candidates, and it maintains an investor portal for shareholders and other interested parties. The company operates in the biotechnology and pharmaceutical sector, with a specific emphasis on oncology and the biology of lipid signaling. This area of research explores how lipids and related signaling molecules influence cellular processes, including those relevant to cancer development and progression. Artelo Biosciences Limited presents itself as a research-driven organization, with dedicated sections of its website explaining its scientific approach and the programs it is advancing. As a UK-registered entity, Artelo Biosciences Limited is based in Alderley Edge, a village in Cheshire, England. The company's online presence serves as its primary channel for communicating its science, pipeline, and investor information. The available evidence does not specify the company's founding year, founders, ownership structure, or listing status. The company appears to be active and focused on the discovery and development of lipid-signaling-based therapeutics for cancer.
Products and positioning
A research-driven biopharmaceutical company focused on lipid-signaling pathways to improve cancer treatments.
Therapeutic candidates targeting lipid-signaling pathways
Drug development programs aimed at modifying lipid-signaling pathways to improve treatments for people living with cancer.
Recent events
Reported
Artelo Biosciences appoints Tamara A. Seymour to its board[4]
Artelo Biosciences announced the appointment of Tamara A. Seymour to its board of directors.
- Unconfirmed
Artelo Biosciences and Trinity partner on cancer cachexia research[5]
Trinity researchers will partner with Artelo Biosciences to study the company’s molecule ART27.13 in preclinical models of human cancer cachexia.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/artelo-biosciences-limited-united-kingdom · Editorial policy · How profiles are compiled